President Trump is poised to name Heidi Overton, a top conservative policy aide, as the next commissioner of the Food and Drug Administration (FDA). Overton has held the position of deputy director at the White House Domestic Policy Council since 2017, contributing significantly to health policies during his administration. Her nomination has raised eyebrows given her history with controversial health policies.

Overton's medical expertise includes a degree in clinical investigation from Johns Hopkins Bloomberg School of Public Health and a medical degree from the University of New Mexico School of Medicine. She notably defended former FDA commissioner Marty Makary, who faced numerous controversies during his tenure. This move could signal a continuation of conservative policies at the helm of the FDA.

However, Overton’s policy positions on abortion are contentious. In articles, she has described abortion as ‘corrosive’ to women and portrayed abortion pills as extremely dangerous. These views align with broader conservative efforts to restrict access to abortion pills through regulatory means.

Despite extensive data suggesting that abortion pills are safer than many common medications, Overton's stance could lead to increased scrutiny of reproductive health policies under her leadership at the FDA. Patients and advocates alike will be watching closely as she navigates this complex landscape.